DUX4.6 siRNA in vitro activity in FSHD patient-derived myotubes
RNA-seq (gene expression) · human · 32 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Homo sapiens (human)
- Samples
- 32 samples: 8 conditions, mostly with about 4 replicates eachGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
- Paper
- Development of a DUX4-targeting antibody oligonucleotide conjugate as a therapy for FSHDNucleic acids research · 2026
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE291267_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA1232689 and SRA study SRP568548. Searching any of these in the dataset finder brings you back here.
Supports a case/control comparison: 12 samples read as cases, 8 as controls.
How we read this: 8 replicated groups read from 32 sample titles; they account for 32 of them. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM8832353 FSHD patient-derived primary myotubes (MB02), Non-targeting siRNA control, Replicate 1 FSHD patient-derived pr…
- GSM8832354 FSHD patient-derived primary myotubes (MB02), Non-targeting siRNA control, Replicate 2 FSHD patient-derived pr…
- GSM8832355 FSHD patient-derived primary myotubes (MB02), Non-targeting siRNA control, Replicate 3 FSHD patient-derived pr…
- GSM8832356 FSHD patient-derived primary myotubes (MB02), Non-targeting siRNA control, Replicate 4 FSHD patient-derived pr…
- GSM8832357 FSHD patient-derived primary myotubes (MB02), DUX4.6 siRNA, Replicate 1 FSHD patient-derived pr…
- GSM8832358 FSHD patient-derived primary myotubes (MB02), DUX4.6 siRNA, Replicate 2 FSHD patient-derived pr…
- GSM8832359 FSHD patient-derived primary myotubes (MB02), DUX4.6 siRNA, Replicate 3 FSHD patient-derived pr…
- GSM8832360 FSHD patient-derived primary myotubes (MB02), DUX4.6 siRNA, Replicate 4 FSHD patient-derived pr…
- GSM8832361 FSHD patient-derived primary myotubes (MB05), Non-targeting siRNA control, Replicate 1 FSHD patient-derived pr…
- GSM8832362 FSHD patient-derived primary myotubes (MB05), Non-targeting siRNA control, Replicate 2 FSHD patient-derived pr…
- GSM8832363 FSHD patient-derived primary myotubes (MB05), Non-targeting siRNA control, Replicate 3 FSHD patient-derived pr…
- GSM8832364 FSHD patient-derived primary myotubes (MB05), Non-targeting siRNA control, Replicate 4 FSHD patient-derived pr…
- GSM8832365 FSHD patient-derived primary myotubes (MB05), DUX4.6 siRNA, Replicate 1 FSHD patient-derived pr…
- GSM8832366 FSHD patient-derived primary myotubes (MB05), DUX4.6 siRNA, Replicate 2 FSHD patient-derived pr…
- GSM8832367 FSHD patient-derived primary myotubes (MB05), DUX4.6 siRNA, Replicate 3 FSHD patient-derived pr…
- GSM8832368 FSHD patient-derived primary myotubes (MB05), DUX4.6 siRNA, Replicate 4 FSHD patient-derived pr…
- GSM8832369 FSHD patient-derived primary myotubes (MB06), Non-targeting siRNA control, Replicate 1 FSHD patient-derived pr…
- GSM8832370 FSHD patient-derived primary myotubes (MB06), Non-targeting siRNA control, Replicate 2 FSHD patient-derived pr…
- GSM8832371 FSHD patient-derived primary myotubes (MB06), Non-targeting siRNA control, Replicate 3 FSHD patient-derived pr…
- GSM8832372 FSHD patient-derived primary myotubes (MB06), Non-targeting siRNA control, Replicate 4 FSHD patient-derived pr…
- GSM8832373 FSHD patient-derived primary myotubes (MB06), DUX4.6 siRNA, Replicate 1 FSHD patient-derived pr…
- GSM8832374 FSHD patient-derived primary myotubes (MB06), DUX4.6 siRNA, Replicate 2 FSHD patient-derived pr…
- GSM8832375 FSHD patient-derived primary myotubes (MB06), DUX4.6 siRNA, Replicate 3 FSHD patient-derived pr…
- GSM8832376 FSHD patient-derived primary myotubes (MB06), DUX4.6 siRNA, Replicate 4 FSHD patient-derived pr…
- GSM8832377 Control subject-derived primary myotubes (MB07), Non-targeting siRNA control, Replicate 1 Control subject-derived…
- GSM8832378 Control subject-derived primary myotubes (MB07), Non-targeting siRNA control, Replicate 2 Control subject-derived…
- GSM8832379 Control subject-derived primary myotubes (MB07), Non-targeting siRNA control, Replicate 3 Control subject-derived…
- GSM8832380 Control subject-derived primary myotubes (MB07), Non-targeting siRNA control, Replicate 4 Control subject-derived…
- GSM8832381 Control subject-derived primary myotubes (MB07), DUX4.6 siRNA, Replicate 1 Control subject-derived…
- GSM8832382 Control subject-derived primary myotubes (MB07), DUX4.6 siRNA, Replicate 2 Control subject-derived…
- GSM8832383 Control subject-derived primary myotubes (MB07), DUX4.6 siRNA, Replicate 3 Control subject-derived…
- GSM8832384 Control subject-derived primary myotubes (MB07), DUX4.6 siRNA, Replicate 4 Control subject-derived…
- GSE334189 RNA-seq analysis of global gene expression changes in human FSHD immortalized myotubes following treatment with the BAZ1A inhibitor C06 18 samples shares fshd, myotubes
- GSE302327 HIF-1alpha activity affects stem cell fate in patient-derived ileum organoids 29 samples shares patient-derived, activity
- GSE299603 DUX4 activates a transcriptional network involving Krüppel-like factors KLF17 and KLF18 [KLF17_KLF18_OE] 9 samples shares dux4
- GSE279480 Longitudinally stable T cell and innate immune activity distinguish healthy adult immunotypes I 1021 samples shares activity
- GSE279552 Longitudinally stable T cell and innate immune activity distinguish healthy adult immunotypes [II] 864 samples shares activity
- GSE276935 The activity of tertiary lymphoid structures in high grade serous ovarian cancer is governed by site, stroma, and cellular interactions 417 samples shares activity
- GSE280267 Glycine Receptor Activity in β Cells Is Downregulated in Type 2 Diabetes and After High Glucose Culture 199 samples shares activity
- GSE305224 Covalent pan-TEAD inhibitors block YAP activity and demonstrate brain penetrance in Hippo-dependent cancer models [RNA-seq] 120 samples shares activity
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.